Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1295-1305

  Zeidler, Michelle ^a   Corren, Jonathan ^b   Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allergy Medical Clinic   (United States)

Author keywords

Asthma; Dry powder inhaler; Inhaled corticosteroids; Mometasone furoate; Once daily

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; HYDROCORTISONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MOMETASONE FUROATE; PLACEBO; SALBUTAMOL; SHORT ACTING DRUG; THEOPHYLLINE;

ADD ON THERAPY; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ASTHMA; BACKACHE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRY POWDER; DYSMENORRHEA; DYSPNEA; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; LUNG FUNCTION; MUSCULOSKELETAL PAIN; PHARYNGITIS; PRACTICE GUIDELINE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SHORT SURVEY; SIDE EFFECT; SINUSITIS; THRUSH; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ANTI-ALLERGIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; HUMANS; NEBULIZERS AND VAPORIZERS; PREGNADIENEDIOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77952495439     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003701152     Document Type: Short Survey

References (33)

1. National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2005. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics
2. Chartbook on Cardiovascular, Lung, and Blood Diseases, 2007. Available at: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm [Last accessed 16 February 2008]
3. Canonica GW. Treating asthma as an inflammatory disease. Chest 2006; 130:21-8S
4. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/index.htm [Last accessed 16 April 2008]
5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, updated 2008. Available at: http://www.ginasthma.com/ Guidelineitem.aspl1-2&l2-1&intId 60 [Last accessed 30 August 2009]
6. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487-495
7. Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996;275:931-936
8. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2-to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315-322
9. Asmanex® Twisthaler® (mometasone furoate). Full Prescribing Information, Merck & Co., Inc., Whitehouse Station, NJ, 2008
10. Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174:605-614
11. West S, King V, Carey T, et al. Systems to rate the strength of scientific evidence. Evidence Report/Technology Assessment No. 47. AHRQ Publication No. 02-E016. Rockville, MD: Agency for Healthcare Research and Quality; 2002 April
12. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcrip-tional activation by topically active glucocorticoids. Arzneim-Forsch 1998; 48:956-960
13. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000;40:1227-1236
14. Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and phar-macokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001;23:1339-1354
15. Karpel JP. An easy-to-use dry-powder inhaler. Adv Ther 2000;17:282-286
16. Yang TT, Li S, Wyka B, et al. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001;14:487-494
17. Skoner D, Gentile D. Children with mild asthma achieve peak inspiratory flow rates that allow adequate delivery of mometasone furoate from the Twisthaler® dry powder inhaler [Abstract]. Ann Allergy Asthma Immunol 2008;100, Supplement 1:A28
18. D'Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005; 21:1281-1289
19. Bensch GW, Prenner B, BerkowitzR, etal. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006;96:533-540
20. Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001;86:36-43
21. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-418
22. Corren J, Berkowitz R, Murray JJ, et al. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003;57:567-572
23. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999;93:603-612
24. Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000;106:852-860
25. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000;118:1538-1546
26. Skoner D, Berger WE. Mometasone furoate is effective in children with asthma: Supporting evidence from clinical trials [Abstract]. Am J Respir Crit Care Med 2008;177:A710
27. Berger WE, Milgrom H, Chervinsky P, et al. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol 2006;97:672-680
28. Meltzer EO, Baena-Cagnani CE, Chervinsky P, et al. Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. Pediatr Asthma, Allergy Immunol 2007; 20:67-81
29. Noonan M, Leflein J, Corren J, Staudinger H. Long-term safety of mometa-sone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipro-prionate in children with persistent asthma. BMC Pediatrics 2009;Jul 13;9:43
30. Data on file C97-380. Whitehouse Station, NJ: Merck & Co., Inc., 2008
31. Skoner D, Gentile D, Angelini B. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Allergy Asthma Proc 2010;31:10-19
32. Skoner D, Dunn M, Lee T. Effects of mometasone furoate dry powder inhaler on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma [Abstract]. Am J Respir Crit Care Med 2003; 167:A272
33. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics 2002. Quick Reference. Bethesda MD: National Heart, Lung, and Blood Institute; 2002. Report No.: NIH Publication No. 02-5075